Profile, Treatment, and Survival of Palliative Cancer Patients in a Middle Income Country's Cancer Center

Am J Hosp Palliat Care. 2022 Apr;39(4):456-460. doi: 10.1177/10499091211034772. Epub 2021 Jul 27.

Abstract

Background: Data describing the characteristics, treatment, and survival of oncological patients referred to PCS remains scarce. Aim: To establish the characteristics of oncological patients referred to PCS, including their profile, treatment, and survival within a 7-year period.

Design: Retrospective review of medical records. Clinical variables such as treatment and dates were included. Ji2 or Wilcoxon tests were used accordingly; Kaplan-Meier and log rank test were used to estimate survival.

Setting/participants: Consecutive oncological patients diagnosed between 2012 and 2018 sent to PCS were included.

Results: We studied 5,631 patients, 58% female and 59% at advanced stage. Median age was 59 years, with 6 years or less of formal education and low monthly income ($152.4 USD). Neoplasms included breast (12%), stomach (12%), colorectal (10%) and cervical cancer (9%). Median referral time was 5.1 months; pain was the main reason for referral. Morphine was the most prescribed opioid with 47%. Median overall survival was 3.1 months.

Conclusions: Morphine remains the paradigm of treatment making necessary to emphasize information on its optimal use. Additional measures such as education for cancer prevention and early referral to PCS are vital to improve survival and quality of life.

Keywords: Mexico; end of life; neoplasms; opioids; palliative care; survival.

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morphine
  • Neoplasms* / drug therapy
  • Palliative Care
  • Quality of Life*
  • Retrospective Studies

Substances

  • Analgesics, Opioid
  • Morphine